The 11th International Congress on Targeted Anticancer Therapies (TAT 2013) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.
The 11th International Congress on Targeted Anticancer Therapies (TAT 2013) is designated for a maximum of 17 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
ESMO MORA Credits
ESMO has awarded 17 Cat. 1 ESMO MORA points to the TAT2013 program. The ESMO Medical Oncologist’s Recertification Approval (MORA) is a CME certificate that allows ESMO members to remain certified in medical oncology.
Learning objectives for CME
1. To understand the molecular basis for the design and development of new targeted cancer therapeutics;
2. To become familiar with the biological and clinical properties of emerging and established targeted cancer therapeutics;
3. To understand how early-phase clinical studies of (combinations of) targeted cancer therapeutics are best designed and conducted.